Malignancies in organ transplant recipients

Pathology International

Volumn 54, Issue 9, 2004, Pages 649-658

  Hoshida, Yoshihiko ^a   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Acquired cystic disease of the kidney; Adult T cell lymphoma; Cancer; Epidemiology; Epstein Barr virus; Hemodialysis; Malignancy; p53 gene mutations; Post transplantation lymphoproliferative disorder; Renal cancer; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; OKT 3;

ADULT; BLOOD DONOR; BLOOD TRANSFUSION; BRAIN LYMPHOMA; CANCER; CANCER RISK; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HEMODIALYSIS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE DEFICIENCY; IMMUNOSURVEILLANCE; JAPAN; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; ONCOVIRINAE; PRIORITY JOURNAL; RECIPIENT; REVIEW; SKIN CANCER; SYSTEMATIC REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; THYROID CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; JAPAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS;

EID: 4644281627     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2004.01676.x     Document Type: Review

References (88)

1. Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery 1978; 83: 492-502.
2. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183-9.
3. Adami J, Gabel H, Lindelof B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-7.
4. Ochiai T, Asano T, Isono K. Development of malignancies in Japanese renal transplant recipients. Transplantation Proc 1987; 14: 2967-70.
5. Gunji Y, Ochiai T, Asano T et al. Development of malignant tumor in renal transplant recipients and their NK and LAK activity. Jpn J Clin Immun 1990; 13: 236-45.
6. Hoshida Y, Tsukuma H, Yasunaga Y et al. Cancer risk after renal transplantation in Japan. Int J Cancer 1997; 71: 517-20.
7. Penn I. Depressed immunity and the development of cancer. Cancer Detect Prev 1994; 18: 241-52.
8. Gaya SBM, Rees A, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long-term renal transplants. Transplantation 1995; 59: 1705-9.
9. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-8.
10. Hojo M, Morimoto T, Maluccio M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-34.
11. Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA. Does cyclosporine A cause cancer? Nat Med 1999; 5: 714.
12. Swinnen LJ, Constanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723-8.
13. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101-3.
14. Hoshida Y, Li T, Dong Z et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91: 869-75.
15. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-9.
16. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus (ATLV) from cell line of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-5.
17. zur Hausen H, Schulte-Holthausen H, Klein G et al. EBV DNA in biopsied Burkitt tumors and anaplastic carcinoma of the nasopharynx. Nature 1990; 228: 1056-8.
18. Aozasa K, Kanno H, Miwa H, Tomita Y. EBV and malignant lymphoma with special emphasis on pyothorax-associated lymphoma. Curr Top Microbiol Immunol 2001; 258: 103-20.
19. Said W, Chien K, Takeuchi S et al. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood 1996; 87: 4937-43.
20. Mele A, Pulsoni A, Blanco E et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996-9.
21. Vilchez RA, Madden CR, Kozinetz CA et al. Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 2002; 359: 817-23.
22. Nakatsuka S, Liu A, Dong Z et al. Simian virus 40 sequences in malignant lymphomas in Japan. Cancer Res 2003; 63: 7606-8.
23. Kinlen JL, Sheil AGR, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979; 2: 1461-6.
24. Hoshida Y, Xu J-X, Tomita Y et al. Methotrexate (MTX)-associated lymphoproliferative disorders (LPD) in Japan. (Submitted.)
25. Liebowitz D. Epstein-Barr virus and a cellular signalling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338: 1413-21.
26. Gavioli R, De Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci USA 1992; 89: 5862-6.
27. Murray RJ, Kurilla MG, Brooks JM et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157-68.
28. Lee SP, Thomas WA, Murray RJ et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993; 67: 7428-35.
29. Young L, Alfieri C, Hennessy K et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 1080-85.
30. Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv 1992; 13: 53-80.
31. Shibata D, Tokunaga M, Uemura Y, Sato E, Tanaka S, Weiss LM. Association of Epstein-Barr virus with undifferentiated gastric carcinoma with intense lymphoid infiltration. Am J Pathol 1991; 139: 469-74.
32. Qiu K, Tomita Y, Hashimoto M et al. Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: association with clinico-pathologic factors and HLA-subtype. Int J Cancer 1997; 71: 155-8.
33. Shibata D, Tokunaga M, Uemura Y et al. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma like carcinoma. Am J Pathol 1991; 139: 469-74.
34. Tokunaga M, Land CE, Uemura Y et al. Epstein-Barr virus in gastric carcinoma. Am J Pathol 1993; 143: 1250-54.
35. Hoshida Y, Tomita Y, Ohsawa M, Ning X, Aozasa K. Epstein-Barr virus in malignancies in renal transplant recipients in Japan. J Cancer Res Clin Oncol 1997; 123: 509-13.
36. Dockrell DH, Stricker JG, Paya CV. Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients. Clin Infect Dis 1998; 26: 180-82.
37. Quintanilla-Martinez L, Lome-Maldonado C, Schwarzmann F et al. Post-transplantation lymphoproliferative disorders in Mexico: an aggressive clonal disease associated with Epstein-Barr virus type A. Mod Pathol 1998; 11: 200-208.
38. Leblond V, Sutton L, Dorent R et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961-8.
39. Zanke BW, Rush DN, Jeffery JR, Israels LG. HTLV-1 T cell lymphoma in a cyclosporine-treated renal transplant patient. Transplantation 1989; 48: 695-6.
40. The T- and B-cell Malignancy Study Group. Statistical analysis of clinico-pathological, virological, and epidemiological data on lymphoid malignancies with special reference to adult T-cell leukemia/lymphoma: a report of the second nationwide study of Japan. Jpn J Clin Oncol 1985; 15: 517-35.
41. Kubota T, Ikezoe T, Hakoda E, Sawada T, Taguchi H, Miyoshi I. HTLV-1-seronegative, genome-positive adult T cell leukemia: report of a case. Am J Hematol 1996; 53: 133-6.
42. Crowley JP, Nealey TA, Metzger J, Pono L, Chazan JA. Transfusion and long-term hemodialysis. Arch Intern Med 1987; 147: 1925-8.
43. Opelz G. Effect of HLA matching in 10,000 cyclosporine-treated cadaver kidney transplants. Transplant Proc 1987; 19: 641-6.
44. Lee SY, Matsushita K, Machida J, Tajiri M, Yamaguchi K, Takatsuki K. Human T-cell leukemia virus type I infection in hemodialysis patients. Cancer 1987; 60: 1474-8.
45. Tamura I, Koda T, Kobayashi Y, Ichimura H, Kurimura O, Kurimura T. Prevalence of four blood-borne viruses (HBV, HCV, HTL-1, HIV) among haemodialysis patients in Japan. J Med Virol 1992; 36: 271-3.
46. zur Hausen H. Human genital cancer: synergism between two virus infections or synergism between a virus infection and initial events. Lancet 1986; 2: 1370-72.
47. Barbosa MS, Vass WC, Lowy DR et al. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 1991; 65: 292-8.
48. Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA, Bird CC. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 1997; 75: 722-5.
49. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7.
50. Roth D, Fernandez JA, Babinschkin S et al. Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med 1992; 117: 470-75.
51. Schroter GP, Weil R, Penn I et al. Hepatocellular carcinoma associated with chronic hepatitis B virus infection after kidney transplantation. Lancet 1982; 2: 381-2.
52. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106-12.
53. Hanto DW, Gajl-Peczalska KJ, Frizzera G et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg 1983; 198: 356-69.
54. Chadburn A, Suciu-Foca N, Cesarman E et al. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995; 14: 1862-70.
55. Hjelle B, Evans-Holm M, Yen TSB, Catooy M, Guis M, Edman JC. A poorly differentiated lymphoma of donor origin in a renal allograft recipient. Transplantation 1989; 47: 945-8.
56. Meduri G, Fromentin L, Vieillefond A, Fries D. Donor-related non-Hodgkin's lymphoma in a renal allograft recipient. Transplant Proc 1991; 23: 2649.
57. Spiro IJ, Yandell DW, Li C et al. Lymphoma of donor origin occurring in the porta hepatis of a transplanted liver. N Engl J Med 1993; 329: 27-9.
58. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of society for hematopathology workshop. Sem Diag Pathol 1997; 14: 8-14.
59. Patton DF, Wikowski CW, Honson CA et al. Epstein-Barr virus-determined clonality in posttransplant lymphoproliferative disease. Transplantation 1990; 49: 1080-84.
60. Chadburn A, Chen JM, Hsu DT et al. The morphologic and molecular genetic categories of post-transplantation lymphoproliferative disorders are clinically relevant. Cancer 1998; 82: 1978-87.
61. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-65.
62. Gaidano G, Carbone A, Dalla-Favera R. Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J Natl Cancer Inst Monogr 1998; 23: 95-100.
63. Edwards RH, Raab-Traub N. Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphoma. J Virol 1994; 68: 1309-15.
64. Tokunaga M, Uemura Y, Tokudome T et al. Epstein-Barr virus related gastric cancer in Japan; A molecular pathoepidemiological study. Acta Path Jpn 1993; 43: 574-81.
65. Hoshida Y, Hongyo T, Nakatsuka S et al. Gene mutations in lymphoproliferative disorders of T and NK/T cell phenotypes developing in renal transplant patients. Lab Invest 2002; 82: 257-64.
66. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84: 2412-21.
67. Macon WR, Williams ME, Greer JP et al. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood 1996; 87: 1474-83.
68. His ED, Picken MM, Alkan S. Post-transplantation lymphoproliferative disorder of the NK-cell type: a case report and review of the literature. Mod Pathol 1998; 11: 479-84.
69. Natkunam Y, Warnke RA, Zehnder JL, Cornbleet PJ. Aggressive natural killer-like T-cell malignancy with leukemic presentation following solid organ transplantation. Am J Clin Pathol 1999; 111: 663-71.
70. Hughson MD, Hennigar GR, McManus JFA. Atypical cysts, acquired renal cystic disease, and renal cell tumors in end stage dialysis kidneys. Lab Invest 1980; 42: 475-80.
71. Dunnill MS, Millard PR, Oliver D. Acquired cystic disease of the kidneys: a hazard of long-term intermittent maintenance haemodialysis. J Clin Pathol 1977; 30: 868-77.
72. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 1993; 22: 135-9.
73. Ishikawa I. Renal cell carcinoma in chronic dialysis patients: A 1990 questionnaire study in Japan. Kidney Int 1993; 43: S167-9.
74. Hoshida Y, Nakanishi H, Shin M, Satoh T, Hanai J, Aozasa K. Renal neoplasias in patients receiving dialysis and renal transplantation. Clinico-pathological features and p53 gene mutations. Transplantation 1999; 68: 385-90.
75. Ishikawa I. Acquired cysts and neoplasms of the kidneys in renal allograft recipients. Contrib Nephrol 1992; 100: 254-68.
76. Ishikawa I, Saito Y, Onouchi Z et al. Development of acquired cystic disease and adenocarcinoma of the kidney in glomerulonephritic chronic hemodialysis patients. Clin Nephrol 1980; 14: 1-6.
77. Kovacs G, Fuzesi L, Emanuel A, Kung H. Cytogenetics of papillary renal cell tumors. Genes Chrom Cancer 1991; 3: 249-55.
78. Kovacs G. Molecular differential pathology of renal cell tumours. Histopathology 1993; 22: 1-8.
79. Bugert P, Kovacs G. Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 1996; 149: 2081-8.
80. Ono K, Yasukohchi A, Kikawa K. Pathogenesis of acquired renal cysts in hemodialysis patients; the role of oxalate crystal deposition in renal tubules. Trans Am Soc Artif Intern Organs 1987; 33: 245-9.
81. Cohen EP, Elliott WC Jr. The role of ischemia in acquired cystic kidney disease. Am J Kidney Dis 1990; 15: 55-60.
82. Acquired cystic disease of the kidney. Lancet 1977; 2: 1063.
83. Kirkwood RG, Dunn S, Thomasson L, Simenhoff ML. Generation of the precarcinogen dimethylnitrosamine (DMNA) in dialysate water. Trans Am Soc Artif Intern Organs 1981; 27: 168-71.
84. Lee ES, Locker J, Nalesnik M et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995; 332: 19-25.
85. McClain KL, Leach CT, Jenson HB et al. Association of Epstein-Barr virus leiomyosarcoma in young people with AIDS. N Engl J Med 1995; 332: 12-18.
86. Somers GR, Tesoriero AA, Hartland E et al. Multiple leiomyosarcomas of both donor and recipient origin arising in a heart-lung transplant patient. Am J Surg Pathol 1998; 22: 1423-8.
87. Pen I. Kaposi's sarcoma in transplant recipients. Transplantation 1997; 64: 669-73.
88. Al-Sulaiman MH, Al-Khader AA. Kaposi's sarcoma in renal transplant recipients. Transplant Sci 1994; 4: 46-60.